Pancreatic Cancer Research

ResearcherChristian-Albrechts-Universität zu KielActive in the last 2 years

Anna Maxi Wandmacher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9349-2520; OpenAlex author ID A5077013829. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 4 papers

Papers 8

  1. Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer. Co-author DOI 10.1016/j.biopha.2026.119257↗
  2. Intratumoral microbiome and pancreatic cancer: an enabling hallmark and path to novel treatments? Co-author DOI 10.1038/s41416-025-03324-7↗
  3. Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-026-01663-z↗
  4. L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the complex tumor stroma Co-author DOI 10.64898/2026.08.10.743835↗
  5. Pancreatic Cancer Highlights from the European Society for Medical Oncology Annual Meeting 2024 in Barcelona. Last author DOI 10.1159/000547154↗
  6. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2023.1157397↗
  7. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. Co-author DOI 10.3390/cancers13164235↗
  8. The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. First author DOI 10.3390/cancers13194932↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Susanne Sebens · 7 shared papers, 2021–2026 · strength 1.63
  2. Christoph Röcken · 4 shared papers, 2023–2026 · strength 0.85
  3. Rüdiger Braun · 3 shared papers, 2026 · strength 0.69
  4. Annika Bräuer · 3 shared papers, 2026 · strength 0.69
  5. Anne‐Sophie Mehdorn · 3 shared papers, 2021–2026 · strength 0.69
  6. Daniela Wesch · 3 shared papers, 2023–2026 · strength 0.63
  7. Benjamin Heckelmann · 2 shared papers, 2026 · strength 0.46
  8. Tina Daunke · 2 shared papers, 2023–2026 · strength 0.39
  9. Silje Beckinger · 2 shared papers, 2023–2026 · strength 0.39
  10. Sabrina Sulzer · 1 shared paper, 2025 · strength 0.37
  11. Marianne Sinn · 1 shared paper, 2025 · strength 0.37
  12. Malte Carstensen · 1 shared paper, 2026 · strength 0.33
  13. Meghna Basu · 1 shared paper, 2026 · strength 0.33
  14. Lisa-Marie Philipp · 1 shared paper, 2026 · strength 0.33
  15. Rainer Lothar Heuchel · 1 shared paper, 2026 · strength 0.24
  16. Jan-Paul Gundlach · 1 shared paper, 2026 · strength 0.24
  17. Tobias Keck · 1 shared paper, 2026 · strength 0.22
  18. Louisa Bolm · 1 shared paper, 2026 · strength 0.22
  19. Corinna Ulrike Keber · 1 shared paper, 2026 · strength 0.22
  20. Steffen Deichmann · 1 shared paper, 2026 · strength 0.22
  21. Kim C. Honselmann · 1 shared paper, 2026 · strength 0.22
  22. Jens Uwe Marquardt · 1 shared paper, 2026 · strength 0.22
  23. Ulrich Friedrich Wellner · 1 shared paper, 2026 · strength 0.22
  24. Benedikt Färber · 1 shared paper, 2026 · strength 0.22
  25. Sascha Rahn · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.